Lates News

Beam Therapeutics (BEAM.US): In Q3 2025, the revenue reached 9.698 million US dollars, compared to the previous value of 14.269 million US dollars, and the expected value of 12.831 million US dollars; earnings per share were -1.10 US dollars, compared to the previous value of -1.17 US dollars, and the expected value of -1.01 US dollars.